Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-02-28 · accession 0000919574-25-001777 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-03-04 | 2025-02-28 | LAB | Casdin Capital, LLC | Dir, 10% | J - Other | $1.07 | 0 | 59.39M | New | $0 |
| I | 2025-03-04 | 2025-02-28 | LAB | Casdin Capital, LLC | Dir, 10% | P - Purchase | $1.07 | +4.82M | 58.85M | +9% | +$5.16M |
| 2025-03-04 | 2025-02-28 | LAB | Casdin Capital, LLC | Dir, 10% | A - Grant | $1.07 | +58.2K | 2.81M | +2% | +$62.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-28 | J | D | 545,000 | $1.07 | 0 | I See footnote | — | — | (F3) The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. |
| 2 | Common | Common Stock | 2025-02-28 | J | A | 545,000 | $1.07 | 59,391,780 | I See footnote | — | — | (F1) The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| 3 | Common | Common Stock | 2025-02-28 | P | A | 4,820,959 | $1.07 | 58,846,780 | I See footnote | — | — | (F1) The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| 4 | Common | Common Stock | 2025-02-28 | A | A | 58,215 | $1.07 | 2,806,470 | D | — | — | (F4) Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. (F5) The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member. (F6) Includes RSUs. (F7) The securities are owned directly by Eli Casdin. |